ipilimumab,nivolumab
bms
['colorectal', 'niche-2', 'rectal']
the #oncoalerttoptweet #esmo22 day 3 tweet by our oncoalert colleague niche-2 for tx naive dmmr #colorectalcancer, nonmetastatic, demonstrates &gt; 95% major path response after short term #immunotherapy treatment. best, 
?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ??